<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153227</url>
  </required_header>
  <id_info>
    <org_study_id>CEIm 2019/643</org_study_id>
    <nct_id>NCT04153227</nct_id>
  </id_info>
  <brief_title>Osteoporosis, Trabecular Bone Score and Fracture Risk Assessment in Male Patients After Radical Cystectomy</brief_title>
  <official_title>Impact on Bone Health in Patients Undergoing Radical Cystectomy: Prevalence of Osteoporosis, Trabecular Bone Score (TBS) Assessment and Fracture Risk by FRAX in Male Patients After One Year of Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical cystectomy is associated with a greater risk of fracture due to long-term metabolic
      consequences of intestinal urinary diversions. One of the mechanisms theoretically involved
      with bone loss after radical cystectomy is metabolic acidosis that inhibits osteoblast
      activity, stimulates osteoclast bone resorption and urinary calcium loss. Other factors as
      advanced age, diabetes or chronic renal failure may increase the effect of metabolic
      acidosis. Moreover, osteoporosis in men remains under-diagnosed and under-appreciated.

      Although metabolic and bone changes after radical cystectomy are well known, bone mineral
      density (BMD) or fracture risk assessment are not recommended in different international
      guidelines during follow-up.

      The objective of this study is to evaluate the fracture risk of male patients undergoing
      radical cystectomy after more than one year of follow-up. Fracture risk assessment will be
      performed by BMD to analyse the prevalence of osteoporosis, vertebral fractures and
      measurement of Trabecular Bone Score (TBS) in combination with the Fracture Risk Assessment
      Tool (FRAX). These results will be correlated with blood markers with the objective to
      determine independent risk factors for osteoporosis or bone fracture in this population.

      To the best of the investigator's knowledge this will be the first study assessing the
      fracture risk after radical cystectomy performance evaluating BMD and the probability of
      fracture at 10 years using the FRAX algorithm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Number of patients with osteoporosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone score</measure>
    <time_frame>Baseline</time_frame>
    <description>Trabecular bone score (TBS) is a lumbar spine dual-energy absorptiometry texture index, which provides information on microarchitecture skeletal quality partially independent of BMD (TBS values &gt;1.310 normal; TBS: 1.310-1.230 microarchitecture partially degraded; TBS &lt;1.230 microarchitecture degraded).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertebral fractures</measure>
    <time_frame>Baseline</time_frame>
    <description>Presence of vertebral fractures evaluated by Vertebral Fracture Assessment (VFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FRAX Assessment Tool</measure>
    <time_frame>Baseline</time_frame>
    <description>FRAX provides country-specific algorithms for estimating individualized 10-year probability of hip and major osteoporotic fracture (FRAX with and without BMD and FRAX with TBS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with metabolic acidosis.</measure>
    <time_frame>Baseline</time_frame>
    <description>Metabolic acidosis is considered if venous serum bicarbonate &lt;23mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with Secondary hyperparathyroidism.</measure>
    <time_frame>Baseline</time_frame>
    <description>Secondary hiperparathyroidism is considered if Serum parathyroid hormone (PTH) &gt;65 pg/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with Serum total 25(OH) vitamin D deficiency.</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum total 25(OH) vitamine D deficiency is considered if &lt;30 ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with moderate-severe chronic kidney disease</measure>
    <time_frame>Baseline</time_frame>
    <description>Glomerular filtration rate (GFR) &lt;60 mL/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with Hypoalbuminemia</measure>
    <time_frame>Baseline</time_frame>
    <description>Hypoalbuminemia is considered if Albumin &lt; 34 g/L</description>
  </other_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Bladder Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bone mineral density (BMD)</intervention_name>
    <description>Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males who underwent radical cystectomy with urinary diversion (ileal conduit or neobladder)
        after at least one year.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who understand, agree to participate and sign the informed consent.

          -  Males older than 50 years old.

          -  Patients undergoing radical cystectomy with ileal conduit or neobladder.

          -  Time over one year after radical cystectomy.

        Exclusion Criteria:

          -  Female gender.

          -  Males below 50 years old.

          -  Radical cystectomy performed less than one year before.

          -  Radical cystectomy with cutaneous ureterostomy.

          -  Patients diagnosed with primary hyperparathyroidism, hyperthyroidism or systemic lupus
             erythematosus.

          -  Patients treated with drugs known to interfere with bone metabolism (including
             hormonal treatment, biphosphonates or Denosumab) or previously diagnosed with
             osteoporosis.

          -  Patients with a history of hemodialysis or renal transplantation.

          -  Patients who are under active treatment with chemotherapy or immunotherapy due to
             bladder tumor progression or the appearance/progression of a second malignancy.

          -  Any patient who does not agree to participate or does not sign the informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Domínguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Parc Taulí</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arturo Domínguez, MD</last_name>
    <phone>+0034 937458407</phone>
    <email>adominguez@tauli.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Domínguez, MD</last_name>
      <phone>+0034 937458407</phone>
      <email>adominguez@tauli.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Arturo Dominguez-Garcia</investigator_full_name>
    <investigator_title>Principal investigator, bladder tumor department coordinator</investigator_title>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Trabecular bone score</keyword>
  <keyword>FRAX</keyword>
  <keyword>Radical cystectomy</keyword>
  <keyword>Fracture risk</keyword>
  <keyword>Metabolic acidosis</keyword>
  <keyword>Vertebral fracture assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

